Retrospective Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2019; 25(46): 6767-6780
Published online Dec 14, 2019. doi: 10.3748/wjg.v25.i46.6767
Clinical relevance of fluorodeoxyglucose positron emission tomography/computed tomography and magnifying endoscopy with narrow band imaging in decision-making regarding the treatment strategy for esophageal squamous cell carcinoma
Kazuhiro Toriyama, Masahiro Tajika, Tsutomu Tanaka, Makoto Ishihara, Yutaka Hirayama, Sachiyo Onishi, Nobumasa Mizuno, Takamichi Kuwahara, Nozomi Okuno, Shinpei Matsumoto, Eiichi Sasaki, Tetsuya Abe, Yasushi Yatabe, Kazuo Hara, Keitaro Matsuo, Tsuneo Tamaki, Yasumasa Niwa
Kazuhiro Toriyama, Nobumasa Mizuno, Takamichi Kuwahara, Nozomi Okuno, Shinpei Matsumoto, Kazuo Hara, Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan
Masahiro Tajika, Tsutomu Tanaka, Makoto Ishihara, Yutaka Hirayama, Sachiyo Onishi, Yasumasa Niwa, Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan
Makoto Ishihara, Department of Gastroenterology, Anjo Kosei Hospital, Anjo 446-8602, Japan
Eiichi Sasaki, Yasushi Yatabe, Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan
Tetsuya Abe, Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan
Keitaro Matsuo, Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan
Tsuneo Tamaki, East Nagoya Imaging Diagnosis Center, Nagoya 464-0044, Japan
Author contributions: Toriyama K designed the study and wrote the initial draft of the manuscript; Tajika M contributed to writing the draft of the manuscript and interpretation of data and assisted in the preparation of the manuscript; Matsuo K contributed to analysis of data; All other authors contributed to data collection and interpretation, and critically reviewed the manuscript; All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Aichi Cancer Center Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient provided written consent to treatment.
Conflict-of-interest statement: Nobumasa Mizuno has received honoraria from NanoCarrier, Eisai, MSD, Dainippon Sumitomo Pharma, Yakult Honsha, Taiho Pharmaceutical, Merck Serono, AstraZeneca, Teijin Pharma, Ono Pharmaceutical, Incyte Inc, ASLAN Pharmaceuticals, Pharma Valley Center, Novartis, and Zeria Pharmaceutical. All other authors have no conflicts of interest related to this article.
Data sharing statement: No additional data are available.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Masahiro Tajika, MD, PhD, Chief Doctor, Doctor, Department of Endoscopy, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. mtajika@aichi-cc.jp
Received: October 20, 2019
Peer-review started: October 20, 2019
First decision: November 10, 2019
Revised: November 21, 2019
Accepted: December 7, 2019
Article in press: December 7, 2019
Published online: December 14, 2019
Core Tip

Core tip: The role of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for determining treatment strategies in patients with superficial esophageal squamous cell carcinoma (ESCC) remains unclear. This study aimed to demonstrate whether the combination of FDG uptake with findings of magnifying endoscopy with narrow band imaging (ME-NBI) was useful for determining the treatment strategy. If the combination of FDG uptake with Type B2 and B3 on ME-NBI was taken as an indicator for radical esophagectomy or definitive chemoradiotherapy, the sensitivity, specificity, and accuracy were 78.3%, 91.5%, and 87.8%, respectively. Combined FDG-PET and ME-NBI was useful for determining the treatment strategies in patients with ESCC.